2019 | Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma
| SCIENTIFIC REPORTS |
2016 | PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
| SCIENTIFIC REPORTS |
2020 | Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer
| SCIENTIFIC REPORTS |
2023 | Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial | JOURNAL OF CLINICAL ONCOLOGY |
2020 | Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma | CANCER |
2014 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
2022 | Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2023 | Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies
| CANCERS |
2017 | Povidone-iodine for the management of oral mucositis during cancer therapy
| Oncology Reviews |
2023 | Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC | CLINICAL CANCER RESEARCH |
2022 | Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2019 | Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors | Cancer Chemotherapy and Pharmacology |
2022 | Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor
| YONSEI MEDICAL JOURNAL |
2009 | Prognosis of pN3 stage gastric cancer
| CANCER RESEARCH AND TREATMENT |
2023 | Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy
| TRANSLATIONAL LUNG CANCER RESEARCH |
2023 | Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
| CANCER RESEARCH AND TREATMENT |
2019 | Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
| YONSEI MEDICAL JOURNAL |
2021 | Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
2020 | Recurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case Report | OCULAR IMMUNOLOGY AND INFLAMMATION |
2020 | Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
| CLINICAL CANCER RESEARCH |
2022 | Role of postoperative radiotherapy in resected adenoid cystic carcinoma of the head and neck
| RADIATION ONCOLOGY |
2022 | SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models
| CLINICAL & TRANSLATIONAL IMMUNOLOGY |
2024 | SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer
| JOURNAL OF CLINICAL ONCOLOGY |
2011 | Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. | ONCOLOGY |
2019 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
| EMBO MOLECULAR MEDICINE |
2022 | The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
| FRONTIERS IN ONCOLOGY |
2020 | The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
| JOURNAL OF THORACIC DISEASE |
2022 | The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer
| EXPERIMENTAL AND MOLECULAR MEDICINE |
2023 | The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer
| KOREAN JOURNAL OF INTERNAL MEDICINE |
2022 | The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
| ESMO OPEN |
2022 | Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22
| TRANSLATIONAL LUNG CANCER RESEARCH |
2022 | Treatment outcomes and radiotherapy deintensification strategies in human papillomavirus-associated tonsil cancer
| RADIATION ONCOLOGY |
2009 | Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea
| CANCER RESEARCH AND TREATMENT |
2021 | Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study | CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS |
2023 | Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea
| DRUGS-REAL WORLD OUTCOMES |
2023 | Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer
| LUNG CANCER |
2019 | YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer | CLINICAL CANCER RESEARCH |
2022 | YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment
| FRONTIERS IN CHEMISTRY |